Misplaced Pages

Tolebrutinib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound

Pharmaceutical compound
Tolebrutinib
Clinical data
Other namesPRN2246; SAR-442168
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • 4-amino-3-(4-phenoxyphenyl)-1-imidazopyridin-2-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC26H25N5O3
Molar mass455.518 g·mol
3D model (JSmol)
SMILES
  • C=CC(=O)N1CCC(C1)N2C3=C(C(=NC=C3)N)N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5
InChI
  • InChI=1S/C26H25N5O3/c1-2-23(32)29-16-6-7-19(17-29)30-22-14-15-28-25(27)24(22)31(26(30)33)18-10-12-21(13-11-18)34-20-8-4-3-5-9-20/h2-5,8-15,19H,1,6-7,16-17H2,(H2,27,28)/t19-/m1/s1
  • Key:KOEUOFPEZFUWRF-LJQANCHMSA-N

Tolebrutinib is an investigational new drug that is being evaluated to treat multiple sclerosis. It is a Bruton's tyrosine kinase (BTK) inhibitor.

References

  1. "Tolebrutinib - Sanofi". AdisInsight. Springer Nature Switzerland AG.
  2. Turner TJ, Brun P, Gruber RC, Ofengeim D (June 2024). "Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis". Drugs in R&D. 24 (2): 263–274. doi:10.1007/s40268-024-00468-4. PMC 11315827. PMID 38965189.
Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: